Policy Title | Policy Number | Effective Date |
---|
Abatacept (Orencia) (PDF) | CP.PHAR.241 | September 1, 2024 |
AbobotulinumtoxinA (Dysport) (PDF) | CP.PHAR.230 | June 1, 2024 |
Acupuncture (PDF) | CP.MP.92 | August 1, 2024 |
Ado-Trastuzumab (Kadcyla) (PDF) | CP.PHAR.229 | June 1, 2024 |
Aducanumab (Aduhelm) (PDF) | CP.PHAR.468 | June 1, 2024 |
Afamelanotide (Scenesse) (PDF) | CP.PHAR.444 | February 1, 2024 |
Aflibercept (Eylea) (PDF) | CP.PHAR.184 | November 1, 2024 |
Agalsidase beta (Fabrazyme) (PDF) | CP.PHAR.158 | July 1, 2024 |
Air Ambulance (PDF) | CP.MP.175 | July 1, 2024 |
Alemtuzumab (Lemtrada) (PDF) | CP.PHAR.243 | June 1, 2024 |
Alglucosidase (Lumizyme) (PDF) | CP.PHAR.160 | July 1, 2024 |
Allogeneic cultured keratinocytes and dermal fibroblasts (StrataGraft)(PDF) | CP.PHAR.562 | February 1, 2024 |
Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-Thalassemia (PDF) | CP.MP.108 | December 1, 2023 |
Allogenic processed thymus tissue-agdc (Rethymic) (PDF) | CP.PHAR.563 | February 1, 2024 |
Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (PDF) | CP.PHAR.94 | February 1, 2024 |
Amisulpride (Barhemsys) (PDF) | CP.PMN.236 | October 1, 2024 |
Amivantamab-vmjw (Rybrevant) (PDF) | CP.PHAR.544 | Janurary 1, 2025 |
Anifrolumab-fnia (Saphnelo) (PDF) | CP.PHAR.551 | March 1, 2025 |
Anti-Inhibitor Coagulant Complex, Human (Feiba) (PDF) | CP.PHAR.217 | February 1, 2024 |
Antithrombin III (ATryn, Thrombate III) (PDF) | CP.PHAR.564 | February 1, 2024 |
Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) | CP.PHAR.506 | Janurary 1, 2025 |
Adzynma (ADAMTS13, recombinant-krhn) (PDF) | CP.PHAR.635 | August 1, 2024 |
Applied Behavioral Analysis Documentation Requirements (PDF) | CP.BH.105 | May 1, 2025 |
Aprepitant (Aponvie, Cinvanti, Emend), (PDF) | CP.PMN.19 | September 1, 2024 |
Articular Cartilage Defect Repairs (PDF) | CP.MP.26 | April 1, 2024 |
Asfotase Alfa (Strensiq) (PDF) | CP.PHAR.328 | December 1, 2022 |
Assistive Reproductive Technology (PDF) | CP.MP.55 | March 1, 2024 |
Atezolizumab (Tecentriq) (PDF) | CP.PHAR.235 | April 1, 2024 |
Atidarsagene autotemcel (Lenmeldy) (PDF) | CP.PHAR.602 | September 1, 2024 |
Attention Deficit Hyperactivity Disorder Assessment and Treatment (PDF) | CP.BH.124 | August 1, 2023 |
Avacincaptad pegol (Izervay) (PDF) | CP.PHAR.641 | March 1, 2025 |
Avalglucosidase Alfa-ngpt (Nexviazyme) (PDF) | CP.PHAR.521 | July 1, 2024 |
Avelumab (Bavencio) (PDF) | CP.PHAR.333 | February 1, 2024 |
Axatilimab-csfr (Niktimvo) (PDF) | CP.PHAR.691 | January 1, 2024 |
Axicabtagene Ciloleucel (Yescarta®) (PDF) | CP.PHAR.362 | February 1, 2024 |
Azacitidine (Vidaza) (PDF) | CP.PHAR.387 | March 1, 2025 |
Baclofen (Gablofen, Lioresal, Lyvispah, Ozobax) (PDF) | CP.PHAR.149 | Janurary 1, 2025 |
Bamlanivimab-etesevimab (LY-CoV555-LY-CoV016) (PDF) | CP.PHAR.532 | July 1, 2023 |
Bariatric Surgery (PDF) | CP.MP.37 | August 1, 2024 |
Behavioral Health Treatment Documentation Requirements (PDF) | CP.BH.500 | July 1, 2024 |
Belantamab mafodotin (Blenrep) (PDF) | CP.PHAR.469 | June 1, 2024 |
Belatacept (Nulojix) (PDF) | CP.PHAR.201 | Janurary 1, 2025 |
Belimumab (Benlysta) (PDF) | CP.PHAR.88 | October 1, 2024 |
Belinostat (Beleodaq) (PDF) | CP.PHAR.311 | March 1, 2025 |
Bendamustine (Bendeka, Treanda) (PDF) | CP.PHAR.307 | March 1, 2025 |
Benralizumab (Fasenra) (PDF) | CP.PHAR.373 | Janurary 1, 2025 |
Beremagene Geperpavec (Vyjuvek) (PDF) | CP.PHAR.592 | September 1, 2024 |
Betibeglogene autotemcel (PDF) | CP.PHAR.545 | October 1, 2024 |
Bevacizumab (Avastin, Mvasi, Zirabev) (PDF) | CP.PHAR.93 | March 1, 2025 |
Bezlotoxumab (Zinplava) (PDF) | CP.PHAR.300 | February 1, 2024 |
Bimatoprost Implant (Durysta)(PDF) | CP.PHAR.486 | June 1, 2024 |
Biofeedback (PDF) | CP.MP.168 | January 1, 2024 |
Biofeedback for Behavioral Health Disorders (PDF) | CP.BH.300 | May 1, 2023 |
Blinatumomab (Blincyto) (PDF) | CP.PHAR.312 | November 1, 2024 |
Bone-Anchored Hearing Aids (PDF) | AR.CP.MP.93 | August 1, 2023 |
Bortezomib (Velcade) (PDF) | CP.PHAR.410 | February 1, 2024 |
Bremelanotide (Vyleesi) (PDF) | CP.PHAR.434 | February 1, 2023 |
Brentuximab Vedotin (Adcetris) (PDF) | CP.PHAR.303 | October 1, 2024 |
Brexanolone (Zulresso) (PDF) | CP.PHAR.417 | June 1, 2024 |
Brexucabtagene Autoleucel (Tecartus) (PDF) | CP.PHAR.472 | April 1, 2024 |
Brivaracetam (Briviact) (PDF) | CP.PMN.297 | Janurary 1, 2025 |
Brolucizumab-dbll (Beovu) (PDF) | CP.PHAR.445 | February 1, 2024 |
Burn Surgery (PDF) | CP.MP.186 | April 1, 2024 |
Buprenorphine implant (Probuphine) (PDF) | CP.PHAR.289 | August 1, 2024 |
C1 Esterase Inhibitors (Berinert Cinryze Haegarda Ruconest) (PDF) | CP.PHAR.202 | September 1, 2024 |
Cabotegravir, Cabotegravir-Rilpivirine (Apretude Cabenuva) (PDF) | CP.PHAR.573 | October 1, 2024 |
Cabazitaxel (Jevtana®) (PDF) | CP.PHAR.316 | June 1, 2024 |
Canakinumab (Ilaris) (PDF) | CP.PHAR.246 | July 1, 2024 |
Caplacizumab-yhdp (Cablivi) | CP.PHAR.416 | June 1, 2024 |
Carbetocin (PDF) | CP.PHAR.546 | Pending FDA Approval |
Carfilzomib (Kyprolis) (PDF) | CP.PHAR.309 | March 1, 2025 |
Casimersen (Amondys 45) (PDF) | CP.PHAR.470 | April 1, 2024 |
Casirivimab and Imdevimab (REGEN-COV) (PDF) | CP.PHAR.520 | July 1, 2023 |
Caudal or Interlaminar Epidural Steroid Injections (PDF) | CP.MP.164 | August 1, 2024 |
Cemiplimab-rwlc (Libtayo) (PDF) | CP.PHAR.397 | Janurary 1, 2025 |
Cerliponase alfa (Brineura) (PDF) | CP.PHAR.338 | October 1, 2024 |
Certolizumab (Cimzia) (PDF) | CP.PHAR.247 | July 1, 2024 |
Cetuximab (Erbitux) (PDF) | CP.PHAR.317 | March 1, 2025 |
Chloramphenicol (PDF) | CP.PHAR.388 | September 1, 2024 |
Ciltacabtagene Autoleucel (Carvykti)(PDF) | CP.PHAR.533 | Janurary 1, 2025 |
Cipaglucosidase alfa-atga--miglustat (Pombiliti-Opfolda) (PDF) | CP.PHAR.567 | May 1, 2024 |
Clinical Trials (PDF) | CP.MP.94 | August 1, 2024 |
Cochlear Implanted Replacements (PDF) | AR.CP.MP.14 | September 1, 2024 |
Collagenase (Xiaflex) (PDF) | CP.PHAR.82 | September 1, 2024 |
Concert Genetic Testing: Aortopathies and Connective Tissue Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Cardiac Disorders (PDF) | V2.2024 | September 1, 2024
|
Concert Genetic Testing: Dermatologic Conditions (PDF) | V2.2024 | September 1, 2024
|
Concert Genetic Testing: Epilepsy, Neurodegenerative, and Neuromuscular Conditions (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Exome and Genome Sequencing for the Diagnosis of Genetic Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Eye Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Gastroenterologic Disorders (non-cancerous) (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: General Approach to Genetic and Molecular Testing (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Hearing Loss (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Hematologic Conditions (non-cancerous) (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Hereditary Cancer Susceptibility (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Immune, Autoimmune, and Rheumatoid Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Kidney Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Lung Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Metabolic, Endocrine, and Mitochondrial Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Non-Invasive Prenatal Screening (NIPS) (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Pharmacogenetics (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Preimplantation Genetic Testing (PDF) | V2.2024 | September 1, 2024
|
Concert Genetic Testing: Prenatal and Preconception Carrier Screening (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss (PDF) | V2.2024 | September 1, 2024 |
Concert Genetic Testing: Skeletal Dysplasia and Rare Bone Disorders (PDF) | V2.2024 | September 1, 2024 |
Concert Genetics Oncology: Algorithmic Testing (PDF) | V2.2024 | September 1, 2024 |
Concert Genetics Oncology: Cancer Screening (PDF) | V2.2024 | September 1, 2024
|
Concert Genetics Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy) (PDF) | V2.2024 | September 1, 2024
|
Concert Genetics Oncology: Cytogenetic Testing (PDF) | V2.2024 | September 1, 2024
|
Concert Genetics Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies (PDF) | V2.2024 | September 1, 2024
|
Continuous Glucose Monitors (PDF) | CP.PMN.214 | Janurary 1, 2025 |
Copanlisib (Aliqopa) (PDF) | CP.PHAR.357 | March 1, 2025 |
Corticosteroid Intravitreal Implants (Iluvien, Ozurdex, Retisert, Yutiq) (PDF) | CP.PHAR.385 | November 1, 2024 |
Corticotropin (H.P. Acthar, Purified Cortrophin Gel) (PDF) | CP.PHAR.168 | May 1, 2023 |
Cosmetic and Reconstructive Procedures (PDF) | CP.MP.31 | October 1, 2024 |
Cosyntropin (Cortrosyn) (PDF) | CP.PHAR.203 | February 1, 2024 |
Crizanlizumab-tmca (Adakveo) (PDF)
| CP.PHAR.449 | February 1, 2024 |
Cytomegalovirus Immune Globulin (Cytogam) (PDF) | CP.PHAR.277 | September 1, 2024 |
Dalteparin (Fragmin) (PDF) | CP.PHAR.225 | March 1, 2022 |
Daprodustat (Jesduvroq) (PDF) | CP.PHAR.628 | August 1, 2024 |
Daptomycin (Cubicin, Cubicin RF) (PDF) | CP.PHAR.351 | September 1, 2024 |
Daratumumab (Darzalex) (PDF) | CP.PHAR.310 | November 1, 2024 |
Darbepoetin Alfa (Aranesp) (PDF) | CP.PHAR.236 | August 1, 2024 |
Daunorubicin and Cytarabine (Vyxeos) (PDF) | CP.PHAR.352 | Janurary 1, 2025 |
DaxibotulinumtoxinA-lanm (Daxxify) (PDF) | CP.PHAR.651 | Janurary 1, 2025 |
Deep Transcranial Magnetic Stimulation for the Treatment of Obsessive Compulsive Disorder (PDF) | CP.BH.201 | August 1, 2024 |
Deferoxamine (Desferal) (PDF) | CP.PHAR.146 | September 1, 2024 |
Degarelix (Firmagon) (PDF) | CP.PHAR.170 | December 1, 2023 |
Delafloxacin (Baxdela) (PDF) | CP.PMN.115 | September 1, 2024 |
Delandistrogene Moxeparvovec-rokl (Elevidys) (PDF) | CP.PHAR.593 | November 1, 2024 |
Delandistrogene Moxeparvovec-rokl (Elevidys) (PDF) | CP.PHAR.593 | Retire by November 1, 2024 |
Denileukin Diftitox-cxdl (Lymphir) (PDF) | CP.PHAR.693 | Janurary 1, 2024 |
Denosumab (Prolia, Xgeva) (PDF) | CP.PHAR.58 | November 1, 2024 |
Desmopressin Acetate (DDAVP, Stimate, Nocdurna, Noctiva) (PDF) | CP.PHAR.214 | February 1, 2024 |
Dexrazoxane (Zinecard, Totect) (PDF) | CP.PHAR.418 | July 1, 2024 |
Diaphragmatic/Phrenic Nerve Stimulation (PDF) | CP.MP.203 | September 1, 2024 |
Disc Decompression Procedures (PDF) | CP.MP.114 | October 1, 2024
|
Discography (PDF) | CP.MP.115 | July 1, 2024 |
Donor Lymphocyte Infusion (PDF) | CP.MP.101 | June 1, 2024 |
Dostarlimab-gxly (Jemperli) (PDF) | CP.PHAR.540 | November 1, 2024 |
Durable Medical Equipment and Orthotics and Prosthetics Guidelines (PDF) | CP.MP.107 | October 1, 2024 |
Durvalumab (Imfinzi) (PDF) | CP.PHAR.339 | November 1, 2024 |
Ecallantide (Kalbitor) (PDF) | CP.PHAR.177 | September 1, 2024 |
Eculizumab (Soliris) (PDF) | CP.PHAR.97 | October 1, 2024 |
Edaravone (Radicava) (PDF) | CP.PHAR.343 | June 1, 2024 |
Efgartigimod alfa-fcab (Vyvgart) (PDF)
| CP.PHAR.555
| Janurary 1, 2025 |
Elapegademase-lvlr (Revcovi) (PDF) | CP.PHAR.419 | June 1, 2024 |
Electric Tumor Treating Fields (Optune) (PDF) | CP.MP.145 | January 1, 2024 |
Elivaldogene autotemcel (Skysona) (PDF) | CP.PHAR.556 | Janurary 1, 2025 |
Elosulfase Alfa (Vimizim) (PDF) | CP.PHAR.162 | June 1, 2024 |
Elotuzumab (Empliciti) (PDF) | CP.PHAR.308 | March 1, 2025 |
Elranatamab-bcmm (Elrexfio) (PDF) | CP.PHAR.652 | Janurary 1, 2025 |
Emapalumab-lzsg (Gamifant) (PDF) | CP.PHAR.402 | April 1, 2024 |
Enfortumab Vedotin-ejfv (Padcev) (PDF) | CP.PHAR.455 | February 1, 2024 |
Enfuvirtide (Fuzeon) (PDF) | CP.PHAR.41 | September 1, 2023 |
Enoxaparin (Lovenox) (PDF) | CP.PHAR.224 | February 1, 2024 |
Epcoritamab-bysp (Epkinly) (PDF) | CP.PHAR.634 | September 1, 2024 |
Epoetin Alfa (Epogen® and Procrit) (PDF) | CP.PHAR.237 | August 1, 2024 |
Epoprostenol (Flolan, Veletri) (PDF) | CP.PHAR.192 | February 1, 2024 |
Eptinezumab-jjmr (Vyepti) (PDF) | CP.PHAR.489 | March 1, 2025 |
Eribulin Mesylate (Halaven) (PDF) | CP.PHAR.318 | Janurary 1, 2025 |
Erwinia Asparaginase (Erwinaze) (PDF) | CP.PHAR.301 | February 1, 2024 |
Etelcalcetide (Parsabiv) (PDF) | CP.PHAR.379 | September 1, 2024 |
Eteplirsen (Exondys 51) (PDF) | CP.PHAR.288 | April 1, 2024 |
Etranacogene Dezaparvovec (Hemgenix) (PDF) | CP.PHAR.580 | March 1, 2025 |
Evinacumab-dgnb (Evkeeza) (PDF) | CP.PHAR.511 | April 1, 2024 |
Exagamglogene Autotemcel (Exa-Cel) (PDF) | CP.PHAR.603 | July 1, 2024 |
Experimental Technologies (PDF) | CP.MP.36 | June 1, 2024 |
Facet Joint Interventions (PDF) | CP.MP.171 | Janurary 1, 2025 |
Facility-based Sleep Studies for Obstructive Sleep Apnea (PDF) | CP.MP.248 | June 1, 2024 |
Factor VIIa, Recombinant (NovoSeven RT, SevenFact) (PDF) | CP.PHAR.220 | September 1, 2024 |
Factor VIII (Human Recombinant) (PDF) | CP.PHAR.215 | June 1, 2024 |
Factor VIII/von Willebrand Factor Complex (Human - Alphanate®, Humate-P®, Wilate®) (PDF) | CP.PHAR.216 | June 1, 2024 |
Factor IX (Human, Recombinant) (PDF) | CP.PHAR.218 | June 1, 2024 |
Factor IX Complex, Human (Profilnine) (PDF) | CP.PHAR.219 | June 1, 2024 |
Factor XIII, Human (Corifact®) (PDF) | CP.PHAR.221 | February 1, 2024 |
Factor XIII A-Subunit, Recombinant (Tretten®) | CP.PHAR.222 | February 1, 2024 |
Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (PDF) | CP.PHAR.456 | August 1, 2024 |
Faricimab (Vabysmo) (PDF) | CP.PHAR.581 | October 1, 2024 |
Fecal Incontinence Treatments (PDF) | CP.MP.137 | August 1, 2024 |
Ferric Carboxymaltose (Injectafer) (PDF) | CP.PHAR.234 | September 1, 2024 |
Ferric Derisomaltose (Monoferric) (PDF) | CP.PHAR.480 | November 1, 2024 |
Ferric Derisomaltose (Monoferric) (PDF) | CP.PHAR.480 | Retire by November 1, 2024 |
Ferric Pyrophosphate Citrate (Triferic) (PDF) | CP.PHAR.624 | June 1, 2024 |
Ferumoxytol (Feraheme) (PDF) | CP.PHAR.165 | September 1, 2024 |
Fertility Preservation (PDF) | CP.MP.130 | March 1, 2024 |
Fetal Surgery in Utero for Prenatally Diagnosed Malformations (PDF) | CP.MP.129 | November 1, 2024 |
Fibrinogen concentrate (human) (Fibryga, RiaSTAP) (PDF) | CP.PHAR.526 | November 1, 2024 |
Fidanacogene Elaparvovec-dzkt (Beqvez) (PDF) | CP.PHAR.643 | Janurary 1, 2025 |
Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix) (PDF) | CP.PHAR.297 | Retire by November 1, 2024 |
Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix) (PDF) | CP.PHAR.297 | November 1, 2024 |
Fondaparinux (Arixtra) (PDF) | CP.PHAR.226 | March 1, 2022 |
Fosdenopterin (Nulibry) (PDF) | CP.PHAR.471 | June 1, 2024 |
Fulvestrant (Faslodex Injection) (PDF) | CP.PHAR.424 | October 1, 2023 |
Functional MRI (PDF) | CP.MP.43 | April 1, 2024 |
Galsulfase (Naglazyme) (PDF) | CP.PHAR.161 | June 1, 2024 |
Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing (PDF) | CP.MP.209 | August 1, 2023 |
Gastric Electrical Stimulation (PDF) | CP.MP.40 | July 1, 2024 |
Gemtuzumab (Mylotarg) (PDF) | CP.PHAR.358 | Janurary 1, 2025 |
Gender-Affirming Procedures (PDF) | CP.MP.95 | September 1, 2024 |
Givosiran (Givlaari) (PDF) | CP.PHAR.457 | April 1, 2024 |
Glofitamab-gxbm (Columvi) (PDF) | CP.PHAR.636 | September 1, 2024 |
Golodirsen (Vyondys 53) (PDF) | CP.PHAR.453 | April 1, 2024 |
Golimumab (Simponi, Simponi Aria) (PDF) | CP.PHAR.253 | September 1, 2024 |
Goserelin Acetate (Zoladex) (PDF) | CP.PHAR.171 | Janurary 1, 2025 |
Granisetron (Kytril, Sancuso, Sustol) (PDF) | CP.PMN.74 | Janurary 1, 2025 |
Hemin (Panhematin) (PDF) | CP.PHAR.181 | February 1, 2024 |
Histrelin (Vantas, Supprelin LA) (PDF) | CP.PHAR.172 | July 1, 2024 |
Home and Community Based Services (HCBS) (PDF) | AR.CP.BH.503 | October 1, 2024 |
Home Births (PDF) | CP.MP.136 | March 1, 2024 |
Home Ventilators (PDF) | CP.MP.184 | October 1, 2024 |
Hospice Services (PDF) | CP.MP.54 | November 1, 2024 |
Hyaluronate Derivatives (PDF) | CP.PHAR.05 | Janurary 1, 2025 |
Hydroxyprogesterone caproate (Makena) (PDF) | CP.PHAR.14 | June 1, 2024 |
Hyperhidrosis Treatments (PDF) | CP.MP.62 | June 1, 2024 |
ibalizumab-uiyk (Trogarzo) (PDF) | CP.PHAR.378 | August 1, 2024 |
Ibandronate Injection (Boniva) (PDF) | CP.PHAR.189 | April 1, 2024 |
Idecabtagene vicleucel (Abecma) (PDF) | CP.PHAR.481 | Janurary 1, 2025 |
Idursulfase (Elaprase) (PDF) | CP.PHAR.156 | June 1, 2024 |
Iloprost (Ventavis) (PDF) | CP.PHAR.193 | February 1, 2024 |
Imetelstat (Rytelo) (PDF) | CP.PHAR.690 | September 1, 2024 |
Imiglucerase (Cerezyme) (PDF) | CP.PHAR.154 | June 1, 2024 |
Immune Globulins (PDF) | CP.PHAR.103 | Januraray 1, 2025 |
Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea (PDF) | CP.MP.180 | January 1, 2024 |
Implantable Intrathecal or Epidural Pain Pump (PDF) | CP.MP.173 | Janurary 1, 2025 |
Implantable Loop Recorder (PDF) | CP.MP.243 | June 1, 2024 |
Implantable Wireless Pulmonary Artery Pressure Monitoring (PDF) | CP.MP.160 | June 1, 2024 |
Inclisiran (Leqvio) (PDF) | CP.PHAR.568 | April 1, 2024 |
IncobotulinumtoxinA (Xeomin) (PDF) | CP.PHAR.231 | October 1, 2024 |
Inotersen (Tegsedi) (PDF) | CP.PHAR.405 | February 1, 2023 |
Inebilizumab (PDF) | CP.PHAR.458 | October 1, 2024 |
Infertility and Fertility Preservation (PDF) | CP.PHAR.131 | March 1, 2025 |
Infliximab (Remicade, Inflectra, Renflexis) (PDF) | CP.PHAR.254 | October 1, 2024 |
Inotuzumab Ozogamicin (Besponsa) (PDF) | CP.PHAR.359 | Janurary 1, 2025 |
Intensity-Modulated Radiotherapy (PDF) | CP.MP.69 | September 1, 2024 |
Interferon Gamma- 1b (Actimmune) (PDF) | CP.PHAR.52 | February 1, 2024 |
Intestinal and Multivisceral Transplant (PDF) | CP.MP.58 | July 1, 2023 |
Intradiscal Steroid Injections for Pain Management (PDF) | CP.MP.167 | September 1, 2024 |
Iobenguane I-131 (Azedra) (PDF) | CP.PHAR.459 | February 1, 2024 |
Ipilimumab (Yervoy) (PDF) | CP.PHAR.319 | June 1, 2024 |
Irinotecan Liposome (Onivyde) (PDF) | CP.PHAR.304 | Janurary 1, 2025 |
Isatuximab-irfc (Sarclisa)(PDF) | CP.PHAR.482 | June 1, 2024 |
Isavuconazonium (Cresemba) | CP.PMN.154
| June 1, 2024 |
IV Moderate Sedation, IV Deep Sedation, and General Anesthesia for Dental Procedures (PDF) | CP.MP.61 | October 1, 2024 |
Ixekizumab (Taltz) (PDF) | CP.PHAR.257 | June 1, 2023 |
Ketamine (Ketalar) (PDF) | CP.PMN.296 | September 1, 2024 |
Lanadelumab-fylo (Takhzyro) (PDF) | CP.PHAR.396 | September 1, 2024 |
Lanreotide (Somatuline Depot) (PDF) | CP.PHAR.391 | Janurary 1, 2025 |
Lantidra (donislecel): Allogenic Pancreatic Islet Cellular Therapy (PDF) | CP.MP.250 | September 1, 2024 |
Laronidase (Aldurazyme) (PDF) | CP.PHAR.152 | June 1, 2024 |
Lecanemab-irmb (Leqembi) (PDF) | CP.PHAR.596 | March 1, 2025 |
Lefamulin (Xenleta) (PDF) | CP.PMN.219 | September 1, 2024 |
Letermovir (Prevymis) (PDF) | CP.PHAR.367 | January 1, 2025 |
Letermovir (Prevymis) (PDF) | CP.PHAR.367 | Retire by January 1, 2025 |
Leucovorin Injection (PDF) | CP.PHAR.393 | Janurary 1, 2025 |
Leuprolide Acetate (Lupron, Lupron Depot, Eligard, Lupaneta Pack, Fensolvi) (PDF) | CP.PHAR.173 | Janurary 1, 2025 |
Levoleucovorin (Fusilev, Khapzory) (PDF) | CP.PHAR.151 | Janurary 1, 2025 |
Lifileucel (Amtagvi) (PDF) | CP.PHAR.598 | Janurary 1, 2025 |
Linezolid (Zyvox) (PDF) | CP.PMN.27 | October 1, 2024 |
Liposuction for Lipedema (PDF) | CP.MP.244 | July 1, 2024 |
Lisocabtagene maraleucel (Breyanzi) (PDF) | CP.PHAR.483 | August 1, 2024 |
Loncastuximab tesirine-lpyl (Zynlonta) (PDF) | CP.PHAR.539 | September 1, 2024 |
Long Term Care Placement (PDF) | CP.MP.71 | April, 1 2024 |
Lovotibeglogene Autotemcel (Lovo-Cel) (PDF) | CP.PHAR.627 | August 1, 2024 |
Lumasiran (Oxlumo) (PDF) | CP.PHAR.473 | August 1, 2024 |
Lurbinectedin (Zepzelca) (PDF) | CP.PHAR.500 | September 1, 2024 |
Luspatercept-aamt (Reblozyl) (PDF) | CP.PHAR.450 | December 1, 2024 |
Luspatercept-aamt (Reblozyl) (PDF) | CP.PHAR.450 | Retire by December 1, 2024 |
Lutetium Lu 177 Dotatate (Lutathera) (PDF) | CP.PHAR.384 | September 1, 2024 |
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (PDF) | CP.PHAR.582 | June 1, 2024 |
Lysis of Epidural Lesions (PDF) | CP.MP.116 | July 1, 2024 |
Margetuximab-cmkb (Margenza) (PDF) | CP.PHAR.522 | February 1, 2024 |
Mecasermin (Increlex) (PDF) | CP.PHAR.150 | October 1, 2024 |
Mechanical Stretching Devices for Joint Stiffness and Contracture (PDF) | CP.MP.144 | April 1, 2024 |
Melphalan (Hepzato) (PDF) | CP.PHAR.653 | Janurary 1, 2025 |
Melphalan flufenamide (Pepaxto) (PDF) | CP.PHAR.535 | June 1, 2024 |
Mepolizumab (Nucala) (PDF) | CP.PHAR.200 | April 1, 2022 |
Methotrexate (Otrexup, Rasuvo, Xatmep, Reditrex) (PDF) | CP.PHAR.134 | December 1, 2022 |
Methoxy polyethylene glycol-epoetin beta (Mircera) (PDF) | CP.PHAR.238 | August 1, 2024 |
Metreleptin (Myalept) (PDF) | CP.PHAR.425 | September 1, 2024 |
Mirikizumab-mrkz (Omvoh) (PDF) | CP.PHAR.662 | August 1, 2024 |
Mirvetuximab soravtansine-gynx (Elahere) (PDF) | CP.PHAR.617 | July 1, 2024 |
Mitomycin for Pyelocalyceal Solution (Jelmyto) (PDF) | CP.PHAR.495 | September 1, 2024 |
Mitoxantrone (Novantrone) (PDF) | CP.PHAR.258 | July 1, 2024 |
Mogamulizumab-kpkc (Poteligeo) (PDF) | CP.PHAR.139 | March 1, 2025 |
Mometasone Furoate (Sinuva) (PDF) | CP.PHAR.448 | September 1, 2024 |
Mosunetuzumab-axgb (Lunsumio) (PDF) | CP.PHAR.618 | February 1, 2024 |
Motixafortide (Aphexda) (PDF) | CP.PHAR.655 | Janurary 1, 2025 |
Moxetumomab Pasudotox-tdfk (Lumoxiti) (PDF) | CP.PHAR.398 | Janurary 1, 2025 |
Multiple Sleep Latency Testing (PDF) | CP.MP.24 | July 1, 2024 |
Nadofaragene Firadenovec (Instiladrin)(PDF) | CP.PHAR.461 | March 1, 2025 |
Natalizumab (Tysabri) (PDF) | CP.PHAR.259 | September 1, 2024 |
Naxitamab-gqgk (Danyelza) (PDF) | CP.PHAR.523 | February 1, 2024 |
Necitumumab (Portrazza) (PDF) | CP.PHAR.320 | Janurary 1, 2025 |
Nedosiran (Rivfloza) (PDF) | CP.PHAR.619 | August 1, 2024 |
Nemolizumab-ito (Nemluvio) (PDF) | CP.PHAR.703 | Janurary 1, 2025 |
Neuromuscular and Peroneal Nerve Electrical Stimulation (NMES) (PDF) | CP.MP.48 | August 1, 2024 |
Netupitant and Palonosetron (Akynzeo) (PDF) | CP.PMN.158 | September 1, 2024 |
Nerve Blocks and Neurolysis for Pain Management (PDF) | CP.MP.170 | Janurary 1, 2025 |
Nirsevimab (Beyfortus) 08.07.23 (PDF) | CP.PHAR.614 | September 1, 2024 |
Nivolumab (Opdivo) (PDF) | CP.PHAR.121 | Janurary 1, 2025 |
Nivolumab and Relatlimab (Opdualag) (PDF) | CP.PHAR.588 | September 1, 2024 |
No Coverage Criteria (PDF) | CP.PMN.255 | Janurary 1, 2025 |
Nogapendekin alfa inbakicept-pmln (Anktiva) (PDF) | CP.PHAR.684 | September 1, 2024 |
Nonmyeloablative Allogeneic Stem Cell Transplants (PDF) | CP.MP.141 | July 1, 2024 |
Nusinersen (Spinraza®) (PDF) | CP.PHAR.327 | February 1, 2024 |
Obstetrical Home Care Programs (PDF) | CP.MP.91 | July 1, 2024 |
Obinutuzumab (Gazyva) (PDF) | CP.PHAR.305 | Janurary 1, 2025 |
Ocrelizumab (Ocrevus) (PDF) | CP.PHAR.335 | June 1, 2024 |
Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Bynfezia, Mycapssa) (PDF) | CP.PHAR.40 | September 1, 2024 |
Ofatumumab (Arzerra, Kesimpta) (PDF) | CP.PHAR.306 | June 1, 2024 |
Off-Label Use (PDF) | CP.PMN.53 | March 1, 2025 |
Olaparib (Lynparza) (PDF) | CP.PHAR.360 | May 1, 2023 |
Olipudase alfa-rpcp (Xenpozyme) (PDF) | CP.PHAR.586 | September 1, 2024 |
Omadacycline (Nuzyra) (PDF) | CP.PMN.188 | September 1, 2024 |
Omalizumab (Xolair) (PDF) | CP.PHAR.01 | August 1, 2024 |
Omecetaxine (Synribo) (PDF) | CP.PHAR.108 | June 1, 2024 |
Omisirge (omidubicel): Nicotinamide-modified allogeneic hematopoietic progenitor cell therapy (PDF) | CP.MP.249 | August 1, 2024 |
OnabotulinumtoxinA (Botox) (PDF) | CP.PHAR.232 | Janurary 1, 2025 |
Onasemnogene Abeparvovec (Zolgensma) (PDF) | CP.PHAR.421 | September 1, 2024 |
Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) | CP.PHAR.536 | June 1, 2024 |
Orthognathic Surgery (PDF) | CP.MP.202 | October 1, 2024 |
Osteogenic Stimulation (PDF) | CP.MP.194 | September 1, 2024 |
Outpatient Cardiac Rehabilitation (PDF) | CP.MP.176 | September 1, 2024 |
Outpatient Oxygen Use (PDF) | CP.MP.190 | June 1, 2024 |
Paclitaxel protein-bound (Abraxane) (PDF) | CP.PHAR.176 | November 1, 2024 |
Panitumumab (Vectibix) (PDF) | CP.PHAR.321 | March 1, 2025 |
Panniculectomy (PDF) | CP.MP.109 | October 1, 2024 |
Paricalcitol Injection (Zemplar) (PDF) | CP.PHAR.270 | September 1, 2024 |
Pasireotide (Signifor, Signifor LAR) (PDF) | CP.PHAR.332 | Janurary 1, 2025 |
Patisiran (Onpattro) (PDF) | CP.PHAR.395 | July 1, 2024 |
Peanut Allergen Powder-dnfp (Palforzia)(PDF) | CP.PMN.220 | March 1, 2021 |
Pediatric Liver Transplant (PDF) | CP.MP.120 | July 1, 2024 |
Pediatric Oral Function Therapy (PDF) | CP.MP.188 | July 1, 2024 |
Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (PDF) | CP.PHAR.353 | March 1, 2025 |
Pegcetacoplan (Empaveli) (PDF) | CP.PHAR.524 | October 1, 2024 |
Pegfilgrastim (Neulasta, Fulphila, Udenyca, Ziextenzo) (PDF) | CP.PHAR.296 | October 1, 2024 |
Pegloticase (Krystexxa) (PDF) | CP.PHAR.115 | February 1, 2024 |
Pegunigalsidase alfa-iwxj (Elfabrio) (PDF) | CP.PHAR.512 | September 1, 2024 |
Pegvaliase-pqpz (Palynziq) (PDF) | CP.PHAR.140 | Janurary 1, 2025 |
Pegvisomant (Somavert) (PDF) | CP.PHAR.389 | Janurary 1, 2025 |
Pembrolizumab (Keytruda®) (PDF) | CP.PHAR.322 | Janurary 1, 2025 |
Pemetrexed (Alimta, Pemfexy) (PDF) | CP.PHAR.368 | February 1, 2024 |
Percutaneous Left Atrial Appendage Closure for Stroke Prevention (PDF) | CP.MP.147 | July 1, 2024 |
Personal Care Services Authorization (PDF) | ARTC.UM.19 | July 1, 2024 |
Pertuzumab (Perjeta) (PDF) | CP.PHAR.227 | June 1, 2024 |
Pertuzumab-trastuzumab-hyaluronidase-zzxf (Phesgo) (PDF) | CP.PHAR.501 | September 1, 2024 |
Physical, Occupational, and Speech Therapy Services (PDF) | CP.MP.49 | August 1, 2024 |
Plasminogen (Ryplazim) (PDF) | CP.PHAR.513 | Janurary 1, 2025 |
Plerixafor (Mozobil) (PDF) | CP.PHAR.323 | October 1, 2024 |
Polatuzumab Vedotin-piiq (Polivy) (PDF) | CP.PHAR.433 | September 1, 2024 |
Posterior Tibial Nerve Stimulation for Voiding Dysfunction (PDF) | CP.MP.133 | September 1, 2024 |
Pozelimab (REGN3918) (PDF) | CP.PHAR.626 | May 1, 2024 |
Prademagene Zamikeracel (EB-101) (PDF) | CP.PHAR.609 | Pending FDA Approval |
Pralatrexate (Folotyn) (PDF) | CP.PHAR.313 | March 1, 2025 |
Protein C Concentrate, Human (Ceprotin) PDF) | CP.PHAR.330 | February 1, 2024 |
Proton and Neutron Beam Therapies (PDF) | CP.MP.70 | January 1, 2024 |
Ramucirumab (Cyramza) (PDF) | CP.PHAR.119 | February 1, 2024 |
Ranibizumab (Byooviz, Lucentis, Susvimo) (PDF) | CP.PHAR.186 | January 1, 2025 |
Ranibizumab (Byooviz, Lucentis, Susvimo) (PDF) | CP.PHAR.186 | Retire by January 1, 2025 |
Ravulizumab-cwvz (Ultomiris) (PDF) | CP.PHAR.415 | October 1, 2024 |
Reduction Mammoplasty and Gynecomastia Surgery (PDF) | CP.MP.51 | November 1, 2024 |
Repair of Nasal Valve Compromise (PDF) | CP.MP.210 | July 1, 2024 |
Reslizumab (Cinqair) (PDF) | CP.PHAR.223 | February 1, 2024 |
Respiratory Syncytial Virus Vaccine (Abrysvo) C (PDF) | CP.PHAR.658 | Janurary 1, 2025 |
Retifanlimab-dlwr (Zynyz) (PDF) | CP.PHAR.629 | July 1, 2024 |
Rilonacept (Arcalyst) (PDF) | CP.PHAR.266 | July 1, 2024 |
RimabotulinumtoxinB (Myobloc) (PDF) | CP.PHAR.233 | June 1, 2024 |
Risankizumab-rzaa (Skyrizi) (PDF) | CP.PHAR.426 | September 1, 2024 |
Risdiplam (Evrysdi) (PDF) | CP.PHAR.477 | February 1, 2024 |
Rituximab (Rituxan), Rituxan/Hyaluronidase (Rituxan Hycela) (PDF) | CP.PHAR.260 | August 1, 2024 |
Rolapitant (Varubi) (PDF) | CP.PMN.102 | September 1, 2024 |
Romidepsin (Istodax) (PDF) | CP.PHAR.314 | Janurary 1, 2025 |
Romiplostim (Nplate®) (PDF) | CP.PHAR.179 | April 1, 2024 |
Ropeginterferon alfa-2b-njft (Besremi) (PDF) | CP.PHAR.570 | July 1, 2024 |
Rozanolixizumab-noli (Rystiggo) (PDF) | CP.PHAR.648 | March 1, 2025 |
Sacituzumab Govitecan-hziy (Trodelvy) (PDF) | CP.PHAR.475 | June 1, 2024 |
Sacroiliac Joint Fusion (PDF) | CP.MP.126 | October 1, 2024
|
Sacroiliac Joint Interventions for Pain Management (PDF) | CP.MP.166 | September 1, 2024 |
Sargramostim (Leukine) (PDF) | CP.PHAR.295 | October 1, 2024 |
Satralizumab-mwge (Enspryng) (PDF) | CP.PHAR.463 | October 1, 2024 |
Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins and Other Symptomatic Venous Disorders (PDF) | CP.MP.146 | September 1, 2024 |
Sebelipase Alfa (Kanuma) (PDF) | CP.PHAR.159 | June 1, 2024 |
Secukinumab (Cosentyx) (PDF) | CP.PHAR.261 | July 1, 2024 |
Selective Dorsal Rhizotomy for Spasticity in Cerebral Palsy (PDF) | CP.MP.174 | January 1, 2024 |
Selective Nerve Root Blocks and Transforaminal Epidural Steroid Injections (PDF) | CP.MP.165 | September 1, 2024
|
Setmelanotide (Imcivree) (PDF) | CP.PHAR.491 | December 1, 2022 |
Sipuleucel-T (Provenge) (PDF) | CP.PHAR.120 | June 1, 2024 |
Siltuximab (Sylvant) (PDF) | CP.PHAR.329 | February 1, 2024 |
Sirolimus Protein-Bound Particles (Fyarro), topical gel (Hyftor) | CP.PHAR.574 | February 1, 2024 |
Skin and Soft Tissue Substitutes for Chronic Wounds (PDF) | CP.MP.185 | August 1, 2024 |
Sodium thiosulfate (Pedmark) (PDF) | CP.PHAR.610 | May 1, 2024 |
Sotatercept (ACE-011) (PDF) | CP.PHAR.657 | Pending FDA Approval |
Sotrovimab (VIR-7831) (PDF) | CP.PHAR.541 | July 1, 2023 |
Spesolimab-sbzo (Spevigo) (PDF) | CP.PHAR.606 | August 1, 2024 |
Spinal Cord, Peripheral Nerve, and Percutaneous Electrical Nerve Stimulation (PDF) | CP.MP.117 | October 1, 2024
|
Stereotactic Body Radiation Therapy (PDF) | CP.MP.22 | June 1, 2024 |
Sutimlimab-jome (Enjaymo) (PDF) | CP.PHAR.503 | June 1, 2024 |
Tafasitamab-cxix (Monjuvi) (PDF) | CP.PHAR.508 | March 1, 2025 |
Taliglucerase Alfa (Elelyso) (PDF) | CP.PHAR.157 | June 1, 2024 |
Talimogene laherparepvec (Imlygic) (PDF) | CP.PHAR.542 | September 1, 2024 |
Talquetamab-tgvs (Talvey) (PDF) | CP.PHAR.649 | March 1, 2025 |
Tarlatamab-dlle (Imdelltra) (PDF) | CP.PHAR.685 | September 1, 2024 |
Tebentafusp-(Kimmtrak) (PDF) | CP.PHAR.575 | June 1, 2024 |
Teclistamab-cqyv (Tecvayli) (PDF) | CP.PHAR.611 | February 1, 2024 |
Tedizolid (Sivextro) (PDF) | CP.PMN.62 | September 1, 2024 |
Teduglutide (Gattex) (PDF) | CP.PHAR.114 | April 1, 2024 |
Temozolomide (Temodar) (PDF) | CP.PHAR.77 | July 1, 2024 |
Temsirolimus (Torisel) (PDF) | CP.PHAR.324 | Janurary 1, 2025 |
Teplizumab-mzwv (Tzield) (PDF) | CP.PHAR.492 | February 1, 2024 (Previously Pending FDA Approval) |
Teprotumumab (Tepezza) (PDF) | CP.PHAR.465 | February 1, 2024 |
Testosterone (Testopel, Jatenzo) (PDF) | CP.PHAR.354 | Janurary 1, 2025 |
Tezepelumab (Tezspire) (PDF) | CP.PHAR.576 | February 1, 2024 |
Therapeutic Utilization of Inhaled Nitric Oxide (PDF) | CP.MP.87 | July 1, 2024 |
Thyrotropin alfa (Thyrogen) (PDF) | CP.PHAR.95 | September 1, 2024 |
Tildrakizumab-asmn (Ilumya) | CP.PHAR.386 | July 1, 2024 |
Tisagenlecleucel (Kymriah) (PDF) | CP.PHAR.361 | April 1, 2024 |
Tislelizumab-jsgr (Tevimbra) (PDF) | CP.PHAR.687 | November 1, 2024 |
Tisotumab Vedotin-tftv (Tivdak) (PDF) | CP.PHAR.561 | March 1, 2025 |
Tixagevimab-Cilgavimab (Evusheld) (PDF) | CP.PHAR.571 | July 1, 2023 |
Tobramycin (Bethkis, Kitabis Pak, TOBI, TOBI Podhaler) (PDF) | CP.PHAR.211 | March 1, 2022 |
Tocilizumab (Actemra) (PDF) | CP.PHAR.263 | January 1, 2025
|
Tocilizumab (Actemra) (PDF) | CP.PHAR.263 | Retire by January 1, 2025 |
Tofersen (Qalsody) (PDF) | CP.PHAR.591 | Janurary 1, 2025 |
Topotecan (Hycamtin) (PDF) | CP.PHAR.64 | July 1, 2024 |
Toripalimab (Loqtorzi) (PDF) | CP.PHAR.668 | September 1, 2024 |
Total Parenteral Nutrition and Intradialytic Parenteral Nutrition (PDF) | CP.MP.163 | April 1, 2024 |
Trabectedin (Yondelis) (PDF) | CP.PHAR.204 | February 1, 2024 |
Tralokinumab-ldrm (Adbry) (PDF) | CP.PHAR.577 | June 1, 2022 |
Transcatheter Closure of Patent Foramen Ovale (PDF) | CP.MP.151 | January 1, 2024 |
Transcranial Magnetic Stimulation for Treatment Resistant Major Depression (PDF) | CP.BH.200 | August 1, 2024 |
Transplant Service Documentation Requirements (PDF) | CP.MP.247 | April 1, 2024 |
Trastuzumab (Herceptin), Trastuzumab-dkst (Ogivri) (PDF) | CP.PHAR.228 | August 1, 2024 |
Travoprost (iDose TR) (PDF) | CP.PHAR.672 | August 1, 2024 |
Tremelimumab-actl (Imjudo) (PDF) | CP.PHAR.612 | December 1, 2024 |
Tremelimumab-actl (Imjudo) (PDF) | CP.PHAR.612 | Retire by December 1, 2024 |
Treprostinil (Orenitram, Remodulin, Tyvaso) (PDF) | CP.PHAR.199 | February 1, 2024 |
Triamcinolone ER Injection (Zilretta) (PDF) | CP.PHAR.371 | September 1, 2024 |
Trigger Point Injections for Pain Management (PDF) | CP.MP.169 | September 1, 2024 |
Triptorelin pamoate (Trelstar, Triptodur) (PDF) | CP.PHAR.175 | Janurary 1, 2025 |
Ublituximab-xiiy (Briumvi) (PDF) | CP.PHAR.621 | June 1, 2024 |
Urinary Incontinence Devices and Treatments (PDF) | CP.MP.142 | January 1, 2024 |
Ustekinumab (Stelara) (PDF) | CP.PHAR.264 | Janurary 1, 2025 |
Vagus Nerve Stimulation (PDF) | CP.MP.12 | September 1, 2024 |
Valoctocogene Roxaparvovec (PDF) | CP.PHAR.466 | April 1, 2024 (Previously Pending FDA Approval) |
Valrubicin (Valstar) (PDF) | CP.PHAR.439 | March 1, 2025 |
Vedolizumab (Entyvio) (PDF) | CP.PHAR.265 | August 1, 2024 |
Velaglucerase alfa (VPRIV) (PDF) | CP.PHAR.163 | June 1, 2024 |
Velmanase Alfa-tycv (Lamzede) (PDF) | CP.PHAR.601 | June 1, 2024 |
Ventricular Assist Devices (PDF) | CP.MP.46 | April 1, 2024 |
Verteporfin (Visudyne) (PDF) | CP.PHAR.187 | February 1, 2024 |
Vestronidase Alfa-vjbk (Mepsevii) (PDF) | CP.PHAR.374 | July 1, 2024 |
Viltolarsen (Viltepso) (PDF) | CP.PHAR.484 | April 1, 2024 |
Voretigene neparvovec-rzyl (Luxturna) (PDF) | CP.PHAR.372 | February 1, 2024 |
Vosoritide (Voxzogo) (PDF) | CP.PHAR.525 | February 1, 2024 |
Vutrisiran (Amvuttra) (PDF) | CP.PHAR.550 | December 1, 2022 |
Waiver Environmental Modifications Criteria (PDF) | ARTC.CC.25 | September 1, 2022 |
Zavegepant (Zavzpret) (PDF) | CP.PHAR.630 | March 1, 2025 |
Ziv-aflibercept (Zaltrap) (PDF) | CP.PHAR.325 | Janurary 1, 2025 |
Zoledronic Acid (PDF) | CP.PHAR.59 | February 1, 2024 |